Transient Lymphocytic Colitis After SARS-CoV2 mRNA Vaccine

Chey, Samuel W.; Westerhoff, Maria; Chey, William D.

doi:10.14309/ajg.0000000000001673

Cited by 8 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The side effects of mRNA vaccination, such as myocarditis, lymphocytic colitis and fasciitis, are becoming apparent. 41 , 42 , 43 On the one hand, mRNA vaccines need the innate immune system to enhance their ability to induce and tailor antigen‐specific responses. On the other hand, a systemic and persistent inflammatory response can have adverse consequences for the body.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Single‐cell transcriptome atlas reveals protective characteristics of COVID‐19 mRNA vaccine

Tan

Wang

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

Messenger RNA (mRNA) vaccines are promising alternatives to conventional vaccines in many aspects. We previously developed a lipopolyplex (LPP)‐based mRNA vaccine (SW0123) that demonstrated robust immunogenicity and strong protective capacity against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection in mice and rhesus macaques. However, the immune profiles and mechanisms of pulmonary protection induced by SW0123 remain unclear. Through high‐resolution single‐cell analysis, we found that SW0123 vaccination effectively suppressed SARS‐CoV‐2‐induced inflammatory responses by inhibiting the recruitment of proinflammatory macrophages and increasing the frequency of polymorphonuclear myeloid‐derived suppressor cells. In addition, the apoptotic process in both lung epithelial and endothelial cells was significantly inhibited, which was proposed to be one major mechanism contributing to vaccine‐induced lung protection. Cell−cell interaction in the lung compartment was also altered by vaccination. These data collectively unravel the mechanisms by which the SW0123 protects against lung damage caused by SARS‐CoV‐2 infection.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The side effects of mRNA vaccination, such as myocarditis, lymphocytic colitis and fasciitis, are becoming apparent. [41][42][43] On the one hand, mRNA vaccines need the innate immune system to enhance their ability to…”

Section: Discussionmentioning

confidence: 99%

Single‐cell transcriptome atlas reveals protective characteristics of COVID‐19 mRNA vaccine

Tan

Wang

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…There was a case report of a 25-year-old female with an inherited antithrombin deficiency in her sixth week of pregnancy, who died from a severe cerebral venous thrombosis with an onset approximately four weeks after receiving the second mRNA COVID-19 vaccine (Takikawa et al 2022). Other possible long-term adverse effects that could last weeks to months include prolonged gastrointestinal symptoms, such as vomiting, diarrhea, and abdominal pain (Akaishi et al 2022d;Chey et al 2022). To be noted, as the exact causal relationships between COVID-19 vaccines and these serious medical events have yet to be determined, some of the reported symptoms might have been falsely attributed to COVID-19 vaccines.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Acute Adverse Events at a Mass Vaccination Site after the Third and Fourth COVID-19 Vaccinations in Japan

Akaishi

Onodera

Takahashi

et al. 2023

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

The third and fourth doses of the vaccine against coronavirus disease 2019 (COVID-19) were widely administered in Japan since December 2021. Currently, however, data is scarce regarding acute adverse events with the third and fourth doses. The present study reports the profiles of acute adverse events after the third and fourth COVID-19 vaccine doses, seen at the site of a mass vaccination center in Japan. Between December 2021 and July 2022, 267,515 individuals received the third, and 32,934 received the fourth, COVID-19 vaccine dose at the mass vaccination center, of whom 442 recipients of the third (0.19%), and 22 recipients of the fourth (0.07%), dose reported acute adverse events and were examined by doctors on site. The most common diagnosis was vasovagal syncope/presyncope (incidence: 0.01-0.10%), followed by other miscellaneous complaints, acute allergic reactions (0.05-0.005%), and anaphylaxis (< 0.005%). Vasovagal syncope/presyncope occurred most frequently in recipients in those in their 20s, whereas acute allergic reactions were most frequent in those in their 40s. Both reactions were more frequent in women than men. The peak occurrence of vasovagal syncope/presyncope was earlier than 15 min after the injection, whereas that of acute allergic reaction was later than 15 min after the injection. The incidence of acute allergic reactions appeared to differ between various vaccine manufacturers, whereas that of vasovagal syncope/presyncope did not. These real-world data may benefit the safe and efficient implementation of mass vaccination campaigns for citizens who want to receive COVID-19 vaccines now and in the future.

show abstract

“…However, onset of lymphocytic colitis has been observed rarely following SARS-CoV-2 infection with consistently elevated levels of fecal calprotectin and persistent diarrhea, even in the absence of fecal SARS-CoV-2 RNA ( Nassar et al, 2019 ). Moreover, lymphocytic colitis has been reported immediately after the second SARS-CoV-2 mRNA vaccine dose ( Chey et al, 2022 ). The authors additionally performed a review of the Centers for Disease Control and Prevention’s Vaccine Adverse Event Reporting System and revealed further five mRNA vaccine-related cases of microscopic colitis following both Pfizer-BioNTech and Moderna inoculations (three individuals developed severe diarrhea shortly after the second mRNA vaccine dose, whereas two individuals developed diarrhea approximately 1 month after receiving their second dose) ( Chey et al, 2022 ).…”

Section: Sars-cov-2 Infection and Vaccinationmentioning

confidence: 99%

“…Moreover, lymphocytic colitis has been reported immediately after the second SARS-CoV-2 mRNA vaccine dose ( Chey et al, 2022 ). The authors additionally performed a review of the Centers for Disease Control and Prevention’s Vaccine Adverse Event Reporting System and revealed further five mRNA vaccine-related cases of microscopic colitis following both Pfizer-BioNTech and Moderna inoculations (three individuals developed severe diarrhea shortly after the second mRNA vaccine dose, whereas two individuals developed diarrhea approximately 1 month after receiving their second dose) ( Chey et al, 2022 ). All diagnoses were confirmed via colonoscopy with biopsy.…”

Section: Sars-cov-2 Infection and Vaccinationmentioning

confidence: 99%

Microscopic colitis: Etiopathology, diagnosis, and rational management

Nielsen

Fernández‐Bañares

Sato

et al. 2022

eLife

View full text Add to dashboard Cite

Microscopic colitis is an inflammatory bowel disease divided into two subtypes: collagenous colitis and lymphocytic colitis. With an increasing incidence of microscopic colitis exceeding those of ulcerative and Crohn’s disease among elderly people in some countries, microscopic colitis is a debilitating life experience. Therefore, physicians should be familiar with its clinical features and management strategies because the disease deserves the same attention as the classical inflammatory bowel diseases. Here, state-of-the-art knowledge of microscopic colitis is provided from a global perspective with reference to etiopathology and how to establish the diagnosis with the overall aim to create awareness and improve rational management in clinical practice. The immune system and a dysregulated immune response seem to play a key role combined with risk factors (e.g. cigarette smoking) in genetically predisposed individuals. The symptoms are characterized by recurrent or chronic nonbloody, watery diarrhea, urgency, weight loss, and a female preponderance. As biomarkers are absent, the diagnosis relies on colonoscopy with a histological assessment of biopsy specimens from all parts of the colon. Although the disease is not associated with a risk of colorectal cancer, a recent nationwide, population-based cohort study found an increased risk of lymphoma and lung cancer. Budesonide is the first-line therapy for management, whereas immunomodulatory drugs (including biologics) and drugs with antidiarrheal properties may be indicated in those failing, dependent, or intolerant to budesonide. In microscopic colitis induced by checkpoint inhibitors, a drug class used increasingly for a wide range of malignancies, a more aggressive therapeutic approach with biologics introduced early seems reasonable. However, particular attention needs to be drawn to the existence of incomplete forms of microscopic colitis with the risk of being overlooked in routine clinical settings.

show abstract

Transient Lymphocytic Colitis After SARS-CoV2 mRNA Vaccine

Cited by 8 publications

References 11 publications

Single‐cell transcriptome atlas reveals protective characteristics of COVID‐19 mRNA vaccine

Single‐cell transcriptome atlas reveals protective characteristics of COVID‐19 mRNA vaccine

Acute Adverse Events at a Mass Vaccination Site after the Third and Fourth COVID-19 Vaccinations in Japan

Microscopic colitis: Etiopathology, diagnosis, and rational management

Contact Info

Product

Resources

About